Sift Biosciences
Harnessing hidden immunity to fight cancer and autoimmunity.
Seattle, United States · Founded 2024 · $3.7M raised
- Headquarters
- Seattle, Washington
- Employees
- 1–10
- Founded
- 2024
- Business Model
- B2B
- Website
- siftbios.com
- Total Funding
- $3.7M
- Last Round
- $3.7M Pre-SeedFeb 2026
- Rounds
- 1
About
Sift Biosciences is a San Carlos, California-based peptide immunotherapy company spun out of UC Berkeley. The company has built a proprietary platform combining AI-driven discovery, metagenomics, and high-throughput T-cell screening to identify microbially derived peptides that activate pre-existing memory T cells capable of targeting cancer and autoimmune diseases. By borrowing signals from bacteria and viruses that frequently interact with the human immune system, Sift aims to develop a new class of targeted, durable immunotherapies for cancers and autoimmune conditions where current therapies fall short. The company raised $3.7M in an oversubscribed pre-seed round in early 2026 and was co-founded by Yue Clare Lou, Ph.D. (Forbes 30 Under 30) and Maddie Williams.
Summary
Sift Biosciences is a Healthcare company based in Seattle, United States, founded in 2024. It has raised $3.7M in total across 1 round, most recently a $3.7M Pre-Seed round in Feb 2026. Investors include Freeflow Ventures, Lifespan Vision Ventures and SBI US Gateway Fund.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Funding History
Feb 2026
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Specialty pharmaceutical company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...